Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~1. Histologically or cytologically confirmed diagnosis of one of the following DTC subtypes: Papillary thyroid cancer (PTC) or follicular thyroid cancer (FTC).~2. Measurable disease according to (RECIST 1.1) and confirmed by central radiographic review.~3. 131 I-refractory/resistant disease.~4. Evidence of disease progression within 12 months prior to signing informed consent (+1 month screening window).~5. Prior treatment with 0 or 1 vascular endothelial growth-factor (VEGF) or vascular endothelial growth-factor receptors (VEGFR) targeted therapy.~6. Adequate renal, liver, bone marrow, and blood coagulation function, as defined in the protocol.~Exclusion criteria:~1. Anaplastic or medullary carcinoma of the thyroid~2. 2 or more prior VEGF/ VEGFR-targeted therapies~3. Received any anticancer treatment within 21 days or any investigational agent within 30 days prior to the first dose of study drug.~Inclusion criteria for OOL Lenvatinib Treatment Period :~Participants were eligible for lenvatinib treatment in the OOL Lenvatinib Treatment Period if the met the following criteria:~1. Placebo-treated participants in the Randomization Phase who had progressive disease (PD) confirmed by IIR, and who requested treatment with lenvatinib.~2. Participants who continued to satisfy specified inclusion and exclusion criteria as presented in the study protocol.~3. Participants with maximum interval between the day of confirmation of PD by IIR and Cycle 1/Day 1 of the OOL Lenvatinib Treatment Period of less than or equal to 3 months.~4. No systemic anticancer treatment during the interval between the day of confirmation of PD by the IIR and Cycle 1/Day 1 of the OOL Lenvatinib Treatment Period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lenvatinib (Randomization Phase) (Type: EXPERIMENTAL): Participants randomly assigned in a 2:1 ratio to receive blinded study drug (lenvatinib or matching placebo) until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.
- Placebo (Randomization Phase) (Type: PLACEBO_COMPARATOR): Participants randomly assigned in a 2:1 ratio to receive blinded study drug (lenvatinib or matching placebo) until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.
- Lenvatinib 24 mg (OOL Lenvatinib Treatment Period) (Type: EXPERIMENTAL): Participants will receive lenvatinib 24 mg, orally once daily until documentation of disease progression (confirmed by investigator's assessment), development of unacceptable toxicity, or withdrawal of consent. Placebo treated participants in the Randomization Phase who have progressive disease confirmed by IIR could request to receive lenvatinib treatment in the OOL Treatment Period.
- Lenvatinib 20 mg (OOL Lenvatinib Treatment Period) (Type: EXPERIMENTAL): Participants will receive lenvatinib 20 mg, orally once daily until documentation of disease progression (confirmed by investigator's assessment), development of unacceptable toxicity, or withdrawal of consent. Placebo treated participants in the Randomization Phase who have progressive disease confirmed by IIR could request to receive lenvatinib treatment in the OOL Treatment Period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete